Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes

European Journal of Pharmacology

Volumn 649, Issue 1-3, 2010, Pages 390-397

  Zhou, Jiyin ^a   Zhou, Shiwen ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

3T3 L1 cell; Berberine; Peroxisome proliferator activated receptor; Positive transcription elongation factor b; RNA interference; Type 2 diabetes

Indexed keywords

BERBERINE; CYCLIN DEPENDENT KINASE 9; CYCLIN T1; FENOFIBRATE; LIPOPROTEIN LIPASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; ROSIGLITAZONE; SMALL INTERFERING RNA; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ASSAY; CELL SIZE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVITY; FATTY ACID ANALYSIS; GENE EXPRESSION REGULATION; LIPID STORAGE; LOW DRUG DOSE; MALE; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; RNA INTERFERENCE; WHITE ADIPOSE TISSUE; WISTAR RAT;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ADIPOSITY; ANIMALS; BERBERINE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; LIPOPROTEIN LIPASE; MALE; MICE; OBESITY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; POSITIVE TRANSCRIPTIONAL ELONGATION FACTOR B; RATS; RATS, WISTAR; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 78049235146     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.09.030     Document Type: Article

References (37)

1. Berger J., Moller D.E. The mechanisms of action of PPARs. Annu. Rev. Med. 2002, 53:409-435.
2. Bluher M. Adipose tissue dysfunction in obesity. Exp. Clin. Endocrinol. Diab. 2009, 117:241-250.
3. Brusq J.M., Ancellin N., Grondin P., Guillard R., Martin S., Saintillan Y., Issandou M. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J. Lipid Res. 2006, 47:1281-1288.
4. Cai D., Byth K.F., Shapiro G.I. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9. Cancer Res. 2006, 66:435-444.
5. Cawthorn W.P., Sethi J.K. TNF-alpha and adipocyte biology. FEBS Lett. 2008, 582:117-131.
6. Chakrabarti R., Misra P., Vikramadithyan R.K., Premkumar M., Hiriyan J., Datla S.R., Damarla R.K., Suresh J., Rajagopalan R. Antidiabetic and hypolipidemic potential of DRF 2519-a dual activator of PPAR-alpha and PPAR-gamma. Eur. J. Pharmacol. 2004, 491:195-206.
7. Chao S.H., Price D.H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem. 2001, 276:31793-31799.
8. Choi K.C., Ryu O.H., Lee K.W., Kim H.Y., Seo J.A., Kim S.G., Kim N.H., Choi D.S., Baik S.H., Choi K.M. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem. Biophys. Res. Commun. 2005, 336:747-753.
9. Galic S., Oakhill J.S., Steinberg G.R. Adipose tissue as an endocrine organ. Mol. Cell. Endocrinol. 2010, 316:129-139.
10. Garriga J., Grana X. Cellular control of gene expression by T-type cyclin/CDK9 complexes. Gene 2004, 337:15-23.
11. Hou T., Ray S., Brasier A.R. The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression. J. Biol. Chem. 2007, 282:37091-37102.
12. Huang C., Zhang Y., Gong Z., Sheng X., Li Z., Zhang W., Qin Y. Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARgamma pathway. Biochem. Biophys. Res. Commun. 2006, 348:571-578.
13. Iankova I., Petersen R.K., Annicotte J.S., Chavey C., Hansen J.B., Kratchmarova I., Sarruf D., Benkirane M., Kristiansen K., Fajas L. Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis. Mol. Endocrinol. 2006, 20:1494-1505.
14. Kong W., Wei J., Abidi P., Lin M., Inaba S., Li C., Wang Y., Wang Z., Si S., Pan H., Wang S., Wu J., Wang Y., Li Z., Liu J., Jiang J.D. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med. 2004, 10:1344-1351.
15. Lee Y.S., Kim W.S., Kim K.H., Yoon M.J., Cho H.J., Shen Y., Ye J.M., Lee C.H., Oh W.K., Kim C.T., Hohnen-Behrens C., Gosby A., Kraegen E.W., James D.E., Kim J.B. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006, 55:2256-2264.
16. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
17. Luquet S., Gaudel C., Holst D., Lopez-Soriano J., Jehl-Pietri C., Fredenrich A., Grimaldi P.A. Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes. Biochim. Biophys. Acta 2005, 1740:313-317.
18. Morrison R.F., Farmer S.R. Hormonal signaling and transcriptional control of adipocyte differentiation. J. Nutr. 2000, 130:3116S-3121S.
19. Oliver W.R., Shenk J.L., Snaith M.R., Russell C.S., Plunket K.D., Bodkin N.L., Lewis M.C., Winegar D.A., Sznaidman M.L., Lambert M.H., Xu H.E., Sternbach D.D., Kliewer S.A., Hansen B.C., Willson T.M. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA 2001, 98:5306-5311.
20. Park S.K., Oh S.Y., Lee M.Y., Yoon S., Kim K.S., Kim J.W. CCAAT/enhancer binding protein and nuclear factor-Y regulate adiponectin gene expression in adipose tissue. Diabetes 2004, 53:2757-2766.
21. Ramirez-Zacarias J.L., Castro-Munozledo F., Kuri-Harcuch W. Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. Histochemistry 1992, 97:493-497.
22. Schoonjans K., Staels B., Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta 1996, 1302:93-109.
23. Seda O., Sedova L., Oliyarnyk O., Kazdova L., Krenova D., Corbeil G., Hamet P., Tremblay J., Kren V. Pharmacogenomics of metabolic effects of rosiglitazone. Pharmacogenomics 2008, 9:141-155.
24. Sharma A.M., Staels B. Review: Peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J. Clin. Endocrinol. Metab. 2007, 92:386-395.
25. Shim E.Y., Walker A.K., Shi Y., Blackwell T.K. CDK-9/cyclin T (P-TEFb) is required in two postinitiation pathways for transcription in the C. elegans embryo. Genes Dev. 2002, 16:2135-2146.
26. Tan G.D., Olivecrona G., Vidal H., Frayn K.N., Karpe F. Insulin sensitisation affects lipoprotein lipase transport in type 2 diabetes: role of adipose tissue and skeletal muscle in response to rosiglitazone. Diabetologia 2006, 49:2412-2418.
27. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 1979, 76:4350-4354.
28. Tziomalos K., Athyros V.G. Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. Int. J. Nanomedicine 2006, 1:129-147.
29. Wilding J.P. The importance of free fatty acids in the development of Type 2 diabetes. Diabet. Med. 2007, 24:934-945.
30. Yin J., Gao Z., Liu D., Liu Z., Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E148-E156.
31. Yin J., Xing H., Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008, 57:712-717.
32. Zhang Y., Li X., Zou D., Liu W., Yang J., Zhu N., Huo L., Wang M., Hong J., Wu P., Ren G., Ning G. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J. Clin. Endocrinol. Metab. 2008, 93:2559-2565.
33. Zhou Q., Yik J.H. The yin and yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiol. Mol. Biol. Rev. 2006, 70:646-659.
34. Zhou L., Yang Y., Wang X., Liu S., Shang W., Yuan G., Li F., Tang J., Chen M., Chen J. Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism 2007, 56:405-412.
35. Zhou J.Y., Zhou S.W., Zhang K.B., Tang J.L., Guang L.X., Ying Y., Xu Y., Zhang L., Li D.D. Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biol. Pharm. Bull. 2008, 31:1169-1176.
36. Zhou L., Wang X., Shao L., Yang Y., Shang W., Yuan G., Jiang B., Li F., Tang J., Jing H., Chen M. Berberine acutely inhibits insulin secretion from beta-cells through 3', 5'-cyclic adenosine 5'-monophosphate signaling pathway. Endocrinology 2008, 149:4510-4518.
37. Zhou J., Zhou S., Tang J., Zhang K., Guang L., Huang Y., Xu Y., Ying Y., Zhang L., Li D. Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats. Eur. J. Pharmacol. 2009, 606:262-268.